The actions of DPP4 mimic the atherogenic actions of hyperinsulinemia, and DPP4 inhibition in pro-atherosclerotic preclinical models resulted in a reduction of inflammatory and oxidative stress mechanisms, improved endothelial dysfunction, and reduced the development of atherosclerosis [40,41,42]. The gene discussed is DPP4; the disease is hyperinsulinism.